Short answer
Arbutus Biopharma Corp (ABUS) filed its Q3 2025 10-Q quarterly report on Nov 13, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $529,000 (down 60.5% year over year) with net income of −$8M.
Q3 2025 key financials · XBRL
- Revenue
- $529,000
- −60.5% YoY · −95.1% QoQ
- Net income
- −$8M
- +60.7% YoY · −406.9% QoQ
- Operating margin
- -1636.9%
- EPS (diluted)
- −$0.04
- +60.0% YoY · −500.0% QoQ
Source: XBRL data from the Arbutus Biopharma Corp (ABUS) Q3 2025 10-Q on SEC EDGAR. USD.
Arbutus Biopharma Corp Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Clinical-stage biopharma focused on imdusiran and AB-101 for chronic hepatitis B
- Workforce reduced 57%; $12.4M one-time restructuring charge in Q1 2025
- IM-PROVE II low-dose nivolumab cohort best performer: 25% functional cure among low-HBsAg patients
- Near-term focus on pipeline evaluation, cost reduction, and LNP litigation with Moderna trial scheduled March 2026
Risk Factors
- No newly added risk factors; company reported no material changes from the December 31, 2024 Form 10-K
- No materially updated risk identified during the quarter
- No new regulatory, legal, or compliance risk disclosed
- No new operational, competitive, or market risk disclosed
- No new liquidity, debt, currency, or concentration risk disclosed
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Arbutus Biopharma Corp quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.